Background {#S0001}
==========

Multidrug-resistant tuberculosis (MDR-TB) is a major problem in global TB control. In 2017, there were an estimated 558,000 new cases of rifampin (RIF) resistant TB (RR-TB), and 82% of which were MDR-TB.[@CIT0001] India, China and the Russian Federation accounted for almost half of the world's cases of MDR/RR-TB, and there were about 58,000 new cases of MDR/RR-TB in China.[@CIT0001]

Anhui province is located in the eastern part of mainland China, with a jurisdiction area of 140,100 square kilometers. At the end of 2017, the resident population was 62.548 million, and the per capita gross domestic product was 6200 dollars. Since 2004, a TB network monitoring system covering the whole province has been gradually established. 33,607 people with TB were reported in 2017, including 10,341 sputum smear-positive TB patients (SSPTBPs) (The data were obtained from the China TB network surveillance system).

The prevention and treatment work for MDR-TB patients started late in Anhui province. In 2012, the prevention and treatment of MDR-TB patients were carried out in Anqing, Fuyang and Ma'anshan city by relying on the Global Fund Program.[@CIT0002] After two years, the diagnosis and management of MDR-TB were officially launched in this province. When the Global Fund Program ended in 2016, the screening of MDR-TB patients was low with only 278 MDR-TB patients reported through the network. Historically, Anhui province participated in the 4 national TB epidemiological surveys. Since Anhui province was only a site in the national sample survey, and the sample size and sampling design mainly focused on the representativeness of TB prevalence in general, the obtained drug resistance results were not representative of the actual drug resistance level. In addition, a nationwide drug resistance baseline survey was conducted in 2007; these results showed MDR-TB prevalence rate in all TB patients, new TB patients and previously treated TB patients was 8.32% (401/3929), 5.71% (175/3037), and 25.64% (226/892), respectively.[@CIT0003] Since only 4 survey sites were set up in Anhui province, the results did not reflect the overall situation of Anhui province.

Domestic and foreign research reports indicated MDR-TB was closely related to a number of factors such as sociodemographic factors, economic level, and past anti-TB treatment courses,[@CIT0004]--[@CIT0014] and these factors may differ by region or country. MDR-TB risk factors were not yet determined in Anhui province.[@CIT0015] The TB Prevention and Treatment Institute of Anhui province conducted a study to determine the prevalence of MDR-TB and analyzed the risk factors for MDR-TB in Anhui province.

Methods {#S0002}
=======

In 2015, there were 86 TB clinics in Anhui province, covering 105 counties (districts) in 16 cities. It is estimated that in 2015, the prevalence of HIV among the entire population and TB patients in our province was 0.16% and 0.02% (102/35,550), which are all in a low epidemic situation. We did a prospective study from 2015 to 2016, and HIV was not test.

Sampling Method {#S0002-S2001}
---------------

\(1\) A stratified cluster sampling method was used to obtain a representative sample by referring to the monitoring program of the World Health Organization (WHO) Guidelines for surveillance of drug resistance in tuberculosis (Fourth Edition).[@CIT0016]

2) We only chose sputum smear-positive specimens for culture, because the possibility of positive culture was very low for sputum smear-negative specimens, and subsequent drug sensitivity testing (DST) cannot be carried out.

3\) The sample size is calculated according to the statistical requirements of the cross-sectional survey. Sample size formula: n= deff\* (N\*z\^2 p(1-p))/(d\^2 (N-1)+z\^2 p(1-p)), where parameter N, the total number of SSPTBPs reported in the past year, was estimated according to the number in 2014 (N=11,151). The estimated resistance rate of RIF in new cases and previously treated cases was 0.07 (p=0.07), accuracy d=±1.4% and 0.3 (p=0.3), accuracy d=±6%, respectively, credibility was set to 95%, z=1.96, design effect deff=2.[@CIT0003],[@CIT0016] Then the sample size required for new cases of SSPTBPs is 2290, and the sample size required for previously treated cases is 440.

4\) After comprehensive consideration of the sample size required for this survey, the time limit for completing the survey within one year and the number of TB patients actually diagnosed and treated at each survey site each year, 40 survey sites were finally selected. Then each survey site should recruit 57 new cases and 11 previously treated cases of SSPTBPs.

5\) For stratified cluster sampling, the units of sampling are city-level or county-level (district-level) TB diagnosis and treatment units, mainly including city-level, county-level (district-level) disease prevention and control centers and TB designated hospitals.

6\) Specific steps for sampling ([Figure 1](#F0001){ref-type="fig"}). Step 1 is to sort the administrative division code of TB prevention and control planning units in Anhui province. Step 2 is to collect the number of SSPTBPs registered and reported by all TB prevention and treatment planning implementation units in 2014, and list the cumulative number of SSPTBPs. Step 3 is to determine the sampling interval, which is equal to the cumulative number of SSPTBPs divided by the number of units to be sampled. Step 4 is to use the random number table to generate a random number, and the planning unit corresponding to the number of cumulative SSPTBPs is the first survey site. Step 5 is to determine the second to the 40th survey site ([Figure 2](#F0002){ref-type="fig"}) according to the same sampling interval. If the investigation site determined by random sampling cannot undertake the investigation due to special circumstances such as region, traffic or the number of patients, they can be replaced or supplemented downward in the prefecture-level cities under which the investigation sites belongs. In principle, the number of investigation sites replaced shall not exceed 5% of the total investigation sites.Figure 1Specific steps for sampling.Figure 2Layout of the county (district) administrative divisions covered by 40 survey sites.

Case Inclusion Principles {#S0002-S2002}
-------------------------

The following principles were followed in the inclusion of cases at each investigation site: 1) During the investigation, new cases and previously treated cases should be included in the survey consecutively from the beginning to the end according to the registration time, and they could be stopped after reaching the specified number of samples. 2) The investigated cases were newly registered cases from September 15, 2015to August 31, 2016. 3) There was no age range limited for the included cases. 4) TB clinic doctors register and classify the TB patients by asking their medical history. New cases refer to TB patients who have not received any anti-TB treatment course or who received anti-TB treatment course for less than one month. Previously treated cases include four groups of patients: relapse, return after loss to follow-up, treatment failure and re-treatment patients not included in the previous three groups. Re-treatment patients not included in the previous three groups refer to the chronic TB patients treated repeatedly. Recurrence refers to patients with a clear history of anti-TB treatment. After completing the prescribed chemotherapy course, the doctor believed that it had been cured. At this time, the sputum smear was positive or the lesion of the TB patient had obvious activity. Return refers to patients with TB who had been treated for more than one month and whose treatment had been interrupted for more than or equal to two months, and then continued to seek treatment in a medical institution because of clinical symptoms related to TB. Initial treatment failure refers to the smear sputum was positive at the 5th month of anti-TB treatment course. 4) No examination fee was charged for the included patients.

Case Information Collection and the Definition of Variables {#S0002-S2003}
-----------------------------------------------------------

Two trained clinicians obtained signed informed consent from eligible participants. Once informed consent was obtained, a survey questionnaire was administered and completed by each participant to collect sociodemographic data and clinical records about past anti-TB treatment courses. When the respondent was a child younger than 18 years old, the investigator explained the purpose and the content of the investigation to the participant and the legal guardian; the legal guardian signed the informed consent form. Sociodemographic data including sex, age, educational status, and family income in 2014 were collected. Clinical data including household contact with TB patients, past anti-TB treatment courses, the number of anti-TB treatment courses, adverse drug reaction, duration of the first anti-TB treatment course, discontinuation of previous anti-TB treatment courses, and the number of discontinuation of previous anti-TB treatment courses were captured. After completing all the surveys at each survey site, investigators sealed all questionnaires and consent forms, and handed them to the survey coordinators.

One treatment course in "the number of anti-TB treatment courses" refers to one of the following conditions. First, including 6 months of treatment with the "2HRZE/4HR" (H, isoniazid, INH; R, rifampicin; Z, pyrazinamide; E, ethambutol, EMB) chemotherapy regimen, using "3HRZE/4HR" 6HRE chemotherapy regimen for 9 months, and the use of personalized treatment regimen. Second, within the same course of treatment, if the continuous treatment is stopped for no more than 2 months, it is considered as a course of treatment. Third, within the same course of treatment, the drug is discontinued for more than 2 months, and the treatment before the drug discontinuation is regarded as one treatment.

Bacteriological Examination {#S0002-S2004}
---------------------------

Three sputum specimens were obtained from each participant before starting TB treatment. Ziehl-Neelsen staining and smear microscopy for acid-fast bacilli was done on all specimens and the remainder of each specimen was stored at 4 degree Celsius. The best two specimens (highest smear positivity and if only one positive smear, the best smear-negative specimen) were selected for culture and the remainder of the smear-positive specimens stored at −20 degree Celsius. Positive specimens were cultured on lowenstein-jensen (LJ) medium with or without p-nitrobenzoic acid (PNB); growth of *Mycobacterium* TB (M. TB) was inhibited by PNB, while growth of non-TB *Mycobacterium* (NTM) was not affected. Positive cultures from each site were sent to provincial reference laboratories for DST.

DST was performed using the proportion method on LJ medium impregnated with INH, RIF, streptomycin (SM), EMB, ofloxacin (OFL) and kanamycin (KM). The concentrations of anti-TB drugs used were 0.2 μg/mL for INH, 40 μg/mL for RIF,2 μg/mL for EMB, 4 μg/mL for SM, 2 μg/mL for OFL, and 2 μg/mL for KM.[@CIT0017] After completion of all DSTs 10% strains were randomly selected for retesting.

Any drug-resistant TB was defined as resistance to any of the anti-TB drugs among the six drugs (INH, RIF, EMB, SM, OFL or KM). Poly-resistance was defined as resistance to two or more drugs excluding INH and RIF. MDR was defined as resistance to INH and RIF and RR were defined as resistant to RIF. XDR was defined as resistance to at least INH, RIF, OFL, and KM.

Statistical Analysis {#S0002-S2005}
--------------------

The input of the original data was performed by two members of the Tuberculosis Prevention and Treatment Institute of Anhui Province using Epidata software (version 3.1), respectively. Consistency test was carried out on the two databases, and the inconsistent data were determined by the two staff members after checking the original data. Odds ratio (OR) value and 95% confidence intervals (CIs) were used to evaluate the MDR-TB related univariate risk factors. All variables in the univariate analysis were used in the logistic regression analysis modeling for survey data. All relevant variables were initially included in the model, and the forward method was used to select the final variables. The models were compared with the use of the maximum rescaled R^2^ statistic. *P*\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (version 16.0).

Results {#S0003}
=======

Case Inclusion {#S0003-S2001}
--------------

A total of 3047 cases were recruited in the 40 survey sites, including 2502 new cases and 545 previously treated cases. Of these, 2330 (76.5%) were males, while 717 (23.5%) were females. The average age of all cases is 53.59 ± 19.63 years, with a range between 8 years and 96 years old.

Results of DST {#S0004}
==============

Of the 3047 SSPTBPs cases, DST was not done in 517 (16.97%): 275/517 had negative cultures, in 141 NTM was cultured and 101 cultures were contaminated. Finally, 2530 specimens were successfully cultured. DST results are showed in [Table 1](#T0001){ref-type="table"}. The proportions of RR-TB were 11.42% (289/2530, 95% CI: 10.18--12.66%), 7.64% (163/2133, 95% CI: 6.38--8.62%) and 31.74% (126/397,95% CI: 27.38--36.60%), respectively, in all cases, new cases and previously treated cases, and the proportion of MDR-TB was 7.63% (193/2530, 95% CI: 6.59--8.66%), 4.97% (106/2133, 95% CI: 4.05--5.89%) and 21.91% (87/397,95% CI: 17.83--26.00%). The drug resistance rate of previously treated cases to OFL reached 21.66% (17.33--26.75%).Table 1Drug Resistance to First-Line and Second-Line Anti-Tuberculosis Drugs in Anhui, China, 2015--2016Resistance ProfileAll SSPTBPs n=2530New Cases n=2133Previously Treated Cases n=397n% (95% CI)n% (95% CI)n% (95% CI)Any TB Drug Resistance Isoniazid33713.32(11.94--14.82)22310.45(9.13--11.92)11428.72(23.69--34.50) Rifampin28911.42(10.14--12.82)1637.64(6.51--8.91)12631.74(26.44--37.79) Streptomycin32112.69(11.34--14.15)23410.97(9.61--12.47)8721.91(17.55--27.03) Ethambutol742.93(2.30--3.67)401.88(1.34--2.55)348.56(5.93--11.97) Ofloxacin2258.89(7.77--10.13)1396.52(5.48--7.69)8621.66(17.33--26.75) Kanamycin411.62(1.16--2.20)301.41(0.95--2.00)112.77(1.38--4.96) Poly-resistance^a^31412.41(11.08--13.86)1918.96(7.73--10.32)12330.98(25.75--36.97) MDR1937.63(6.59--8.66)1064.97(4.05--5.89)8721.91(17.83--26.00) XDR230.91(0.57--1.36)130.61(0.32--1.04)102.52(1.21--4.63)[^2]

Analysis of Risk Factors for MDR-TB in All Cases {#S0004-S2001}
------------------------------------------------

Of the 2530 cases with DST results, 2529 had completed questionnaires. [Table 2](#T0002){ref-type="table"} shows the analysis results of risk factors for MDR-TB in all SSPTBPs. The univariate analysis results showed that household contact with TB patients, past anti-TB treatment courses, the number of anti-TB treatment courses, duration of the first anti-TB treatment courses, and number of interruptions to past anti-TB treatment courses were related to MDR-TB (*P*\<0.05), while the other factors such as sex, age, educational status, household income in 2014, adverse drug reaction, and past anti-TB treatment interruption had no significant association with MDR-TB (*P*\>0.05). Results of multivariate analysis showed only the number of anti-TB treatment courses was included in the model (*P*=0.004), and cases who received two or more anti-TB treatment courses had a significantly increased risk for developing MDR-TB compared with those who received one anti-TB treatment courses, respectively (OR=5.367, 95% CI=1.258--22.897, *P*\<0.001; OR=13.143, 95% CI=3.487--49.534, *P*\<0.001).Table 2Analysis of Risk Factors for Multidrug-Resistant Tuberculosis (MDR-TB) in All CasesVariablesAll SSPTBPsUnivariate AnalysisMultivariate AnalysisNon-MDRMDRn%Odds Ratio (OR) (95% CI)p-valueAdjusted OR(95% CI)p-valueSex25290.412 Male181314419577.361 Female524485728.391.153(0.820--1.622)0.412Age0.138 0\~707779.091 20\~570426126.860.726(0.314--1.679)0.455 40\~6497872710.731.185(0.526--2.669)0.683 60\~10386511035.890.611(0.270--1.384)0.238Educational status0.303 Illiterate671427135.891 Primary school590496397.671.327(0.866--2.033)0.194 Middle school656707269.641.705(1.146--2.537)0.009 Senior high school265232887.991.387(0.818--2.351)0.225 University15481624.940.830(0.382--1.803)0.638Family income in 20140.362 \<2500254192736.961 2500--4200328263547.341.06(0.574--1.958)0.853 4201--20,000729667958.301.210(0.712--2.056)0.48 20,001--50,000630606908.701.271(0.744--2.173)0.38 \>50,000222112334.720.655(0.310--1.429)0.665Household contact with TB patients0.005 No217516823437.171 Yes1622418612.901.918(1.215--3.028)0.005Past anti-TB treatment courses\<0.001 No200610321094.881 Yes3318942021.195.237(3.854--7.115)\<0.001The number of anti-TB treatment courses\<0.0010.004 12523328511.5811 242246636.364.071(2.202--7.528)\<0.0015.367(1.258--22.897)0.023 ≥340296942.035.089(2.826--9.163)\<0.00113.143(3.487--49.534)0.001Adverse drug reaction0.573 No2355829319.801 Yes982812622.221.179(0.713--1.949)0.522Duration of the first anti-TB treatment courses0.009 6--8 months1634020319.701 \<6 months1402816816.670.822(0.487--1.388)0.463 \>8 months27174438.642.720(1.341--5.515)0.006Discontinuation of previous anti-TB treatment courses0.092 No1974223917.571 Yes1344317724.291.504(0.936--2.417)0.091Number of discontinuation of previous anti-TB treatment courses0.008 183159815.311 21992832.142.429(0.935--6.308)0.068 ≥332195137.253.238(1.489--7.040)0.003

Analysis of Risk Factors for MDR-TB in New Cases {#S0004-S2002}
------------------------------------------------

Among the 2529 SSPTBPs with questionnaire, 2132 patients were new cases. [Table 3](#T0003){ref-type="table"} shows the analysis results of risk factors for MDR-TB in new cases. Univariate analysis did not find that age, sex and other factors were related to the generation of MDR-TB.Table 3Analysis of Risk Factors for Multidrug-Resistant Tuberculosis (MDR-TB) in New CasesVariablesNew CasesUnivariate AnalysisNon-MDRMDRn%Odds Ratio (OR) (95% CI)p-valueSex0.58 Male15507716274.731 Female478275055.351.137(0.725--1.784)0.576Age0.126 0\~697769.211 20\~527275544.870.505(0.212--1.203)0.123 40\~543345775.890.617(0.263--1.446)0.267 60\~888369243.900.4(0.172--0.931)0.034Educational status0.181 Illiterate581236043.811 Primary school496215174.061.070(0.585--1.956)0.827 Middle school570406106.561.773(1.048--2.999)0.033 Senior high school237142515.581.492(0.755--2.949)0.25 University14361494.031.060(0.424--2.651)0.901Family income in 20140.692 \<2500210112214.981 2500--4200283193026.291.282(0.597--2.751)0.524 4201--20,000633326654.810.965(0.478--1.949)0.921 20,001--50,000554305845.141.034(0.509--2.100)0.927 \>50,00019772043.430.678(0.258--1.785)0.432Household contact with TB patients0.41 No18969519914.771 Yes13291416.381.361(0.672--2.757)0.392

Analysis of Risk Factors for MDR-TB in Previously Treated Cases {#S0004-S2003}
---------------------------------------------------------------

A total of 397 valid questionnaires for previously treated cases of SSPTBPs were collected, and [Table 4](#T0004){ref-type="table"} shows the analysis results of risk factors for MDR-TB. Univariate analysis showed that age, the number of anti-TB treatment courses, duration of the first anti-TB treatment courses, discontinuation of previous anti-TB treatment courses, and number of discontinuation of previous anti-TB treatment courses were significantly associated with MDR-TB (*P*\<0.05). Factors such as sex, educational status and household income in 2014 were not related to MDR-TB. When all the above single variable was included in the logistic regression model, only the number of anti-TB treatment courses was included in the model (*P*=0.002). Subgroup analysis results show cases who received two or more anti-TB treatment courses had a significant association with MDR-TB compared with those who received one anti-TB treatment courses (OR=4.544, 95% CI=1.054--19.590, *P*=0.042; OR=11.100, 95% CI=2.913--42.300, *P*\< 0.001).Table 4Analysis of Risk Factors for Multidrug-Resistant Tuberculosis (MDR-TB) in Previously Treated CasesVariablesPreviously Treated CasesUnivariate AnalysisMultivariate AnalysisNon-MDRMDRn%Odds ratio (OR) (95% CI)p-valueAdjusted OR ValuesAdjusted p-valueSex0.056 Male2636733020.301 Female46216731.341.785(0.998--3.194)0.051Age0.008 20\~43155825.861 40\~1064415029.331.190(0.600--2.360)0.619 60\~1602918915.430.523(0.257--1.062)0.073Educational status0.595 Illiterate901910917.431 Primary school942812222.951.395(0.728--2.675)0.316 Middle school863011625.861.634(0.856--3.119)0.137 Senior high school2893724.321.506(0.612--3.702)0.373 University1121315.380.852(0.174--4.160)0.843Family income in 20140.077 \<25004485215.381 2500--42004575213.460.856(0.286--2.560)0.78 4201--20,000953413026.151.968(0.842--4.601)0.118 20,001--50,000773010728.302.143(0.904--5.081)0.084 \>50,0002442814.290.917(0.250--3.361)0.896Household contact with TB patients0.071 No2787335120.801 Yes30154533.331.890(0.966--3.699)0.141Past anti-TB treatment courses No000 Yes3038839122.51The number of anti-TB treatment courses\<0.0010.002 12213325412.9911 242246636.363.827(2.057--7.119)\<0.0014.544(1.054--19.590)0.042 ≥340296942.034.855(2.660--8.864)\<0.00111.100(2.913--42.300)\<0.001Adverse drug reaction0.584 No2135827121.401 Yes892811723.931.155(0.691--1.933)0.582Duration of the first anti-TB treatment courses0.023 6--8 months16040200201 \<6 months1152814319.580.889(0.517--1.527)0.669 \>8 months25174240.482.482(1.222--5.041)0.012Discontinuation of previous anti-TB treatment courses0.038 No1874222918.341 Yes1144315727.391.665(1.026--2.703)0.039Number of discontinuation of previous anti-TB treatment courses0.053 167158218.291 22092931.032.010(0.765--5.279)0.156 ≥333195236.542.572(1.161--5.695)0.02

Discussion {#S0005}
==========

In this study, the proportion of RR in SSPTBPs in Anhui Province was systematically sampled for the first time. Our results showed that the proportion of RR in new cases and previously treated cases was 7.64% (6.38--8.62%) and 31.74% (27.38--36.60%), respectively, which was higher than the national average of 7.1% (5.6--8.7%) and 24% (20--28%), and also above the global average of 4.1% (2.8--5.3%) and 19% (9.8--27%).[@CIT0018] The reasons for the high RR-TB prevalence in this study are not clear and further studies to determine possible reasons are needed. As in other studies, previously treated patients have a higher rate of RR-TB, but even new TB cases had a high rate of RR-TB.[@CIT0019] The reasons for this need to be explored.

Based on the prevalence of MDR-TB from this survey, we estimated that there are approximately 727 MDR-TB patients in Anhui Province in 2017: 451 patients were new cases, accounting for 62%, and 276 patients were previously treated cases, accounting for 38% (The estimation formula: M=Pn×Cn+Pr×Cr, M: total number of MDR-TB patients, Pn: the proportion of MDR-TB in new cases, which equals to 4.97% in this study, Pr: the proportion of MDR-TB in previously treated cases of SSPTBPs, which equals to 21.91%, Cn: the number of new cases in Anhui Province in 2017, which equals to 9071, Cr: the number of previously treated cases in Anhui Province in 2017, which equals to 1259.). However, only 310 MDR-TB patients were actually registered in Anhui Province in 2017, including 107 new cases, accounting for 34.5%, and 203 previously treated cases, accounting for 64.5%. This result suggested new and previously treated TB patients should have DST done so that an appropriate anti-TB treatment regimen can be started in all patients.

This study found that the drug resistance rate of previously treated patients to ofloxacin reached 21.66% (17.33--26.75%), much higher than the average level of 8.7% (6.1--11.2%) in China[@CIT0003] and 17% in Dalian city,[@CIT0007] and close to the WHO-reported rate of resistance to fluoroquinolones (FQs) in global MDR-TB patients (22%).[@CIT0001] High drug resistance of ofloxacin may be related to a number of factors. In China, FQs drugs are the preferred drug for undiagnosed respiratory bacterial infections,[@CIT0020] and readily available on the market. What's more, excessive and premature use of ofloxacin in the anti-TB diagnostic treatment is also one of the reasons. FQs have been recommended as first-line drugs for the treatment of MDR-TB due to their high activity against *M.tuberculosis*. Unfortunately, poorly controlled use of FQs leads to the emergence of FQs resistance in *M.tuberculosis*, which might influence the therapeutic effect for MDR-TB patients.[@CIT0021] Thus, it is significant for us to accept that strict control of the use of FQs is important for the treatment of MDR-TB.

There are still several limitations in this study. First, the cases included in this survey are all SSPTBPs in the outpatient clinic of TB, rather than all TB patients in the population. Therefore, there are certain restrictions when the drug resistance results are extrapolated to all TB patients. Second, the factors affecting the production of MDR-TB are complex. Because the focus of this survey is to understand the prevalence of MDR-TB in Anhui Province, in order to ensure the feasibility of the survey, the influencing factors included in the questionnaire are not comprehensive enough. Foreign research mentioned HIV infection, drug use, and the economic burden and psychological factors of patients are not included in this survey. We will further discuss these factors and MDR-TB in the subsequent study.

Conclusion {#S0006}
==========

The prevalence of MDR-TB was high among the SSPTBPs in Anhui Province, and past anti-TB treatment courses were associated with MDR-TB.

Song Yao and Junwei Yan are co-first authors for this study.
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